Meletios Athanasios D.
- Country
- Greece
- Department
- Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics
Research Overview
- Phase 2, multicenter, open‑label study of extended‑dosing belantamab mafodotin in combination therapy for relapsed/refractory multiple myeloma
- Phase 1/2 Study of REGN17372 in Combination with Linvoseltamab in Participants with Relapsed/Refractory Multiple Myeloma
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 343 of 532 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of mantle cell lymphoma (MCL), a distinct subtype of non-Hodgkin lymphoma. Their research encompasses innovative therapeutic approaches in hematologic malignancies.
- Lymphoid Neoplasms
- Blood Cancer Therapeutics
- B-cell Lymphomas
Particular focus is placed on developing treatment strategies for previously untreated MCL patients.
Therapeutic Development
The investigator evaluates novel therapeutic combinations incorporating targeted therapies with established treatment regimens. Their work includes assessment of combination immunotherapy approaches.
- Novel Drug Combinations
- Immunotherapy Protocols
- Treatment Response Assessment
Research interests include evaluation of treatment efficacy through standardized response criteria.
Clinical Assessment
Expertise in implementing the Lugano Classification for response assessment in lymphoma treatment. The investigator's work involves progression-free survival evaluation in hematologic malignancies.
- Response Criteria Development
- Disease Progression Monitoring
- Treatment Outcome Assessment
Focus includes standardized evaluation methods for treatment effectiveness in lymphoma.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.